文献速递认知障碍与痴呆

全局淀粉样蛋白PET显像对MEMENTO队列未来认知预测的贡献

Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
PubMed 文献 · Neurology · 2024-02-27

在法国MEMENTO队列中,评估全局淀粉样蛋白PET对未来认知的预测增益。纳入510例接受淀粉样蛋白PET且至少4次MMSE评估的受试者,中位随访4.6年。在仅调整人口学特征时,加入淀粉样蛋白负荷可降低预测误差;但纳入既往认知评估后,增益甚微,平均差异不足1个MMSE分。

要点

  • 仅用人口学特征时,加入二分类淀粉样蛋白使MSE降低5.08%(95%CI 0.97%-10.86%)。
  • 纳入1次既往MMSE后,加入连续淀粉样蛋白使MSE降低8.83%(95%CI 2.63%-16.37%)。
  • 有既往认知评估时,加入淀粉样蛋白的预测改善平均不足1个MMSE分。

核心结论

  • 在临床环境中,当已有既往认知评估时,全局淀粉样蛋白负荷未显著改善认知预测。

研究设计与样本

  • 法国MEMENTO队列,纳入老年门诊患者,入组时无痴呆诊断但有早期认知改变。
  • 分析样本为510例接受淀粉样蛋白PET扫描且至少完成4次MMSE评估的受试者。
  • PET扫描时平均年龄71.6岁(标准差7.4),女性占60.7%。
  • 中位随访4.6年(四分位距0.9年)。

主要发现

  • 仅调整人口学特征时,加入二分类淀粉样蛋白使MSE降低5.08%(95%CI 0.97%-10.86%),加入连续淀粉样蛋白使MSE降低12.64%(95%CI 3.35%-25.28%)。
  • 纳入1次既往MMSE时,加入二分类淀粉样蛋白使MSE降低3.51%(95%CI 1.01%-7.28%),加入连续淀粉样蛋白使MSE降低8.83%(95%CI 2.63%-16.37%)。
  • 纳入超过1次既往认知评估时,加入淀粉样蛋白负荷的模型拟合改善更小。
  • 所有纳入既往认知评估的模型中,预测差异平均不足1个MMSE分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Global amyloid-PET is associated with cognition and cognitive decline, but most research on this association does not account for past cognitive information. We assessed the prognostic benefit of amyloid-PET measures for future cognition when prior cognitive assessments are available, evaluating the added value of amyloid measures beyond information on multiple past cognitive assessments. METHODS: The French MEMENTO cohort (a cohort of outpatients from French research memory centers to improve knowledge on Alzheimer disease and related disorders) includes older outpatients with incipient cognitive changes, but no dementia diagnosis at inclusion. Global amyloid burden was assessed using positron emission tomography (amyloid-PET) for a subset of participants; semiannual cognitive testing was subsequently performed. We predicted mini-mental state examination (MMSE) scores using demographic characteristics (age, sex, marital status, and education) alone or in combination with information on prior cognitive measures. The added value of amyloid burden as a predictor in these models was evaluated with percent reduction of the mean squared error (MSE). All models were conducted separately for evaluating the added value of dichotomous amyloid positivity status compared with a continuous amyloid-standardized uptake-value ratio. RESULTS: Our analytic sample comprised 510 individuals who underwent amyloid-PET scans with at least 4 MMSE assessments. The mean age at the PET scan was 71.6 (standard deviation 7.4) years; 60.7% were female. The median follow-up was 4.6 years (interquartile range: 0.9 years). Adding amyloid burden when adjusting for only demographic characteristics reduced the MSE of predictions by 5.08% (95% CI 0.97%-10.86%) and 12.64% (95% CI 3.35%-25.28%) for binary and continuous amyloid, respectively. If the model included 1 past MMSE measure, the MSE improvement was 3.51% (95% CI 1.01%-7.28%) when adding binary amyloid and 8.83% (95% CI 2.63%-16.37%) when adding continuous amyloid. Improvements in model fit were smaller with the addition of amyloid burden when more than 1 past cognitive assessment was included. For all models incorporating past cognitive assessments, differences in predictions amounted to a fraction of 1 MMSE point on average. DISCUSSION: In a clinical setting, global amyloid burden did not appreciably improve cognitive predictions when past cognitive assessments were available. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02164643.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ackley S, Calmasini C, Bouteloup V, et al. Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort. Neurology. 2024. PMID: 38412412. doi:10.1212/WNL.0000000000208054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。